Announced details
Treatment of metastatic colorectal cancer. Improving the efficacy of existing cancer treatments.
No dose-limiting toxicity was observed in the evaluation of the third dose level, 300 mg/m².
3 dose cohorts have been completed through the third dose level.
Isofol is the source of the in-licensed rights to SP-05 and a development partner.
Headquartered in Gothenburg, Sweden, the company is a clinical-stage company developing arfolitixorin. Other attributes: Not disclosed.
Charité – Universitätsmedizin Berlin, Germany
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
World Health Organization (WHO)
| Item | Details |
|---|---|
| Names of Products / Services Covered | SP-05 (Arfolitixorin Sulfate) |
| Counterparty | Isofol Medical AB |
| Counterparty overview | Headquartered in Gothenburg, Sweden, the company is a clinical-stage company developing arfolitixorin. Other attributes: Not disclosed. |
| Relationship with the Company | Isofol is the source of the in-licensed rights to SP-05 and a development partner. |
| Launch date | Second half of 2026 (planned start of the Phase II portion) |
| Applicable area | Treatment of metastatic colorectal cancer. Improving the efficacy of existing cancer treatments. |
| Location | Charité – Universitätsmedizin Berlin, Germany |
| Quantitative Effects | No dose-limiting toxicity was observed in the evaluation of the third dose level, 300 mg/m². |
| Usage history | 3 dose cohorts have been completed through the third dose level. |
| Source | World Health Organization (WHO) |
Items this document does not state (8)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company decided to set 500 mg/m² as the final dose level based on the recommendation of the Safety Evaluation Committee and the favorable results obtained from the 3 dose cohorts conducted to date.